Match Document Document Title
US20110306660 LIQUID CANNABINOID FORMULATIONS  
Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with...
US20140100269 ORAL CANNABINOID FORMULATIONS  
Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with...
US20140314757 PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER  
The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (THC)...
US20120276152 SYSTEMS AND METHODS OF USING ZINC-CHELATOR TO TREAT MYOCARDIAL INFARCTION  
Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.
US20140378539 CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN  
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene...
US20140107192 CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN  
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene...
US20070099987 Treating or preventing diabetes with cannabidiol  
Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
US20150132400 GRANULATE CONTAINING CANNABINOID, METHOD FOR ITS MANUFACTURE AND ORAL DOSAGE UNIT COMPRISING SUCH GRANULATE  
The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within...
US20070231269 Analgesics  
An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the...
US20110033376 Treatment of Melanoma  
There is described dexanabinol, or a derivative thereof, for the treatment of melanoma. There is also described a method of treating a patient suffering from melanoma.
US20130253046 METHODS OF TREATING CANCER COMPRISING TARGETING NQO1  
Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer...
US20110230549 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN  
The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and...
US20100310599 Orally Bioavailable Lipid-Based Constructs  
The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
US20110319352 Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof  
The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to...
US20120003301 TISSUE MARKINGS AND METHODS FOR REVERSIBLY MARKING TISSUE EMPLOYING THE SAME  
Provided are methods of applying a tissue marking to a tissue and rendering said tissue marking colorless when desired, comprising implanting into the tissue an amount of the tissue marking in...
US20140357708 ORAL DOSAGE FORM OF TETRAHYDROCANNABINOL AND A METHOD OF AVOIDING AND/OR SUPPRESSING HEPATIC FIRST PASS METABOLISM VIA TARGETED CHYLOMICRON/LIPOPROTEIN DELIVERY  
An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein...
US20130296415 Manufacturing and Packaging Room Temperature Stable Dronabinol Capsules  
The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an...
US20150004205 BIOMATERIALS HAVING NANOSCALE LAYERS AND COATINGS  
The invention generally relates to surfaces having a protein-resistant hydrogel layer and methods for preparing a protein-resistant hydrogel layer on a surface. The protein-resistant hydrogel...
US20120207809 Method and system for effecting changes in pigmented tissue  
Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are...
US20120043242 Medicinal cannabis fatty foodstuff  
The invention is a product and a process wherein Medicinal Delta-9 tetrahydrocannabinol (Δ9-THC) and potentially other cannabinoids (medicinal cannabis substances) associated with decarboxylated...
US20120015331 SCAFFOLD  
The present invention provides a polymeric scaffold containing an antibacterial photoactive drug and optionally comprising seeded cells such as stem cells. The invention also includes methods of...
US20140221469 PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER  
The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and...
US20120076848 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE  
Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are...
US20130059018 PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER  
This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be...
US20110046213 Production of Delta 9 Tetrahydrocannabinol  
Δ9 THC is obtained by extracting Δ9 THC and Δ9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the Δ9 THC acid into Δ9 THC in the same solvent, without a...
US20120165402 USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY  
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized...
US20110256097 Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle  
Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one...
US20110021564 METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR  
The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities...
US20130116313 Compositions and Methods for Inhibiting G Protein Signaling  
The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in...
US20150105455 WINTERIZED CRUDE CANNABIS EXTRACTS AND METHODS OF PREPARATION AND USE  
The present technology relates to liquid compositions for use in a personal vaporizer. More particularly, the present technology relates to liquid compositions comprising winterized Cannabis...
US20140155361 METHOD FOR TREATING LUNG DISEASE  
Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as β-lapachone. Methods...
US20120142650 METHOD FOR TREATING LUNG DISEASE  
Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as β-lapachone. Methods...
US20110070293 Methods for the Preparation of Liposomes Comprising Docetaxel  
Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or...
US20120183606 DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT  
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of...
US20110104301 METHODS OF REDUCING PAIN AND INFLAMMATION  
Provided herein are methods of treating or preventing pain and/or inflammation in a subject comprising administering to the subject a transient receptor potential (TRP) ion channel inhibitor.
US20120252885 DRONABINOL TREATMENT FOR MIGRAINES  
In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions to treat migraines.
US20110155130 Dronabinol Treatment for Migraines  
In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions to treat migraines.
US20140343136 PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES  
The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment...
US20120114714 METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION  
Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or...
US20110082407 Combination Therapies for the Treatment of Obesity  
Described are pharmaceutical compositions comprising topiramate, phentermine, and metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present...
US20150218121 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME  
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the...
US20120289484 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME  
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the...
US20110152219 USE OF ENHANCERS, POSSIBLY ASSOCIATED TO RIBOFLAVIN, AS WELL AS CORRESPONDING OPHTHALMIC COMPOSITIONS FOR CORNEAL CROSS-LINKING IN THE TREATMENT OF THE KERATOCONUS OR OF OTHER CORNEAL ECTASIC DISORDERS  
The use of enhancers with possibly riboflavin, as well as the corresponding compositions for the treatment of keratoconus or other ectasic corneal disorders by the method of corneal cross-linking.
US20110244057 COMBINATION THERAPIES WITH TOPIRAMATE FOR SEIZURES, RESTLESS LEGS SYNDROME, AND OTHER NEUROLOGICAL CONDITIONS  
The invention provides compositions and methods of treating various conditions, including neurological conditions, with pharmaceutical compositions including a sulfamate (e.g., topiramate) and...
US20140037723 Low Dose Topiramate/Phentermine Composition And Methods Of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20050009903 CB2-selective cannabinoid analogues  
Cannabinoid analogues that exhibit specificity for the CB2 cannabinoid receptor are provided. The analogues are 1-methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Δ8-tetrahydrocannabinols...
US20150126596 METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL  
Methods for making trans-(−)-Δ9-tetrahydrocannabinoI and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinoI composition is prepared by...
US20120277296 Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease  
The present invention relates to selective CB2 agonists for use in the prevention or treatment of alcoholic liver disease and particularly alcoholic hepatic steatosis and liver inflammation, and...
US20130274321 Topical Compositions with Cannabis Extracts  
The present invention provides a method for a topical treatment of a skin cyst. The method includes: applying a formulation to the skin cyst of a mammal; wherein the formulation includes: a...
US20120004251 USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY  
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the...